Deferred treatment of low grade stage T3 prostate cancer without distant metastases.
Fifty patients with extracapsular prostate cancer without known distant metastases were included in a protocol of surveillance followed by deferred treatment of progression. The median observed followup time was 78 months. The risk of developing distant metastases, if not dying before, was 24% and 37% at 5 and 9 years, respectively. The risk of dying of prostate cancer, if not dying of other diseases before, was 12% and 30% at 5 and 9 years, respectively. Thus, the cancer specific survival was 88% at 5 years and 70% at 9 years.
Adolfsson
J
J
Department of Urology, Karolinska Hospital, Stockholm, Sweden.
D000368:Aged; D000369:Aged, 80 and over; D002985:Clinical Protocols; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D016019:Survival Analysis; D013997:Time Factors